A Phase 1/2, Open-Label, Multicenter Study of MDK-703 as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors (ORCHID-1) November 7, 2023
A Phase 1, First in Human, Dose-Escalation Study of UCT-01-097 in Participants With Advanced Solid Tumors November 7, 2023
A Phase I, First in Human, Dose-Escalation Study of UCT-03-008 in Participants withAdvanced Solid Tumors November 7, 2023
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas November 7, 2023
A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors November 7, 2023
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as a Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors November 7, 2023
An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations November 7, 2023
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial November 7, 2023
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination with Pembrolizumab in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies November 7, 2023